Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
Cis-dichlorodiammineplatinum(II) was used in the treatment of 34 patients with advanced adenocarcinoma of the ovary who were resistant to conventional chemotherapy. Two dose schedules were explored: a high-dose schedule with 30 mg/m2 given daily on 3 successive days every 4 weeks and a low-dose schedule with 30 mg/m2 given once every 2-3 weeks. Nine patients (26.5%) showed a therapeutic response with a median duration of 6 months (range, 3-15 months). The main toxic effects included myelosuppression, renal function impairment, and nausea and vomiting. The high-dose schedule proved to be more toxic without any therapeutic advantage.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006454:Hemoglobins; D006801:Humans; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014508:Urea / Q000097:blood; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D006454:Hemoglobins; D014508:Urea; D002945:Cisplatin